Since mutational deactivation of P53 is a prevalent genotype in human cancers 35, our findings suggest that TRIM69 could be a therapeutic target applicable to a wide range of the EYA4-deficient PDAC regardless of their P53 status. The gene discussed is TP53; the disease is cancer.